J Thro Hae:prohibitins可作为心血管疾病药物研发新靶点

2012-01-20 MedSci MedSci原创

 MedSci评论:     对科学的研究需要理性看待,不少研究容易将结果的意义进行放大,即便是发表在一流杂志上的文章,我们也应该用审慎的态度。     Prohibitins是线粒体膜表面一种重要的蛋白,在心血管,脑血管,肿瘤等诸多疾病中,均发挥重要作用,甚至在正常状态,同样十分重要。虽然本研究发现它在血小板的功能

 MedSci评论:

    对科学的研究需要理性看待,不少研究容易将结果的意义进行放大,即便是发表在一流杂志上的文章,我们也应该用审慎的态度。

    Prohibitins是线粒体膜表面一种重要的蛋白,在心血管,脑血管,肿瘤等诸多疾病中,均发挥重要作用,甚至在正常状态,同样十分重要。虽然本研究发现它在血小板的功能中的作用,但是未来能否成为“药靶”,尚未可知。因为一个基因若能成为药靶,则需要它具有相对特异性,或具有相对特异性的调控位点。如果功能过于复杂,影响面很广,则往往并不合适成为药靶。如MAPK等激酶,无法成为调控的药靶。

    近日,国际血栓与止血联合会官方杂志Journal of Thrombosis and Haemostasis在线刊登了中国科学院昆明动物研究所研究人员的最新研究成果“Prohibitins are involved in protease-activated receptor 1-mediated platelet aggregation,”,文章中,作者揭示了潜心血管疾病药物研发的新靶点。

    血小板的主要生理功能是参与止血及血栓形成,并在动脉粥样硬化、肿瘤转移和炎症反应等过程中起着重要的作用。血栓形成是造成心绞痛、心肌梗死、脑梗塞等致命和致残心脑血管疾病的重要因素。血小板激活在血栓性疾病的发病机制中起着重要的作用,通过抑制血小板激活达到防栓、治栓的目的是血栓性心脑血管疾病防治的重要手段之一。凝血酶是体内激活血小板的强力和主要激动剂,凝血酶主要通过激动血小板膜上的蛋白酶激活受体1引起血小板活化和聚集,导致血栓形成。由于蛋白酶激活受体1广泛表达于体内各种组织和细胞,造成药物研发中通过拮抗该受体而抑制血小板活化的策略具有“投鼠忌器”的限制。

    中国科学院昆明动物研究所动物模型与人类疾病机理重点实验室生物毒素与人类疾病课题组在张云研究员带领下,从云南产两栖动物中获得具有激动人血小板的活性多肽单链三叶因子Bm-TFF2,并阐明蛋白酶激活受体1介导了其生物学活性。该课题组张勇和王严戒博士等进一步以Bm-TFF2为分子探针,在国内外首次发现与小鼠不同,抑素蛋白prohibitins在人血小板膜上表达并对血小板激活具有重要的调节功能;拮抗抑素蛋白prohibitins可专一性阻断凝血酶激动蛋白酶激活受体1而诱导的血小板激活。

    该研究成果揭示了人血小板激活调控的新机制,也提供了在基于阻断血小板激活为基础的心脑血管疾病防治创新药物研发中,以抑素蛋白prohibitins作为新药物作用靶点的新策略。

    该研究受到国家973计划项目、国家自然科学基金委重点项目以及基金委-云南省联合基金项目的资助。

doi:10.1111/j.1538-7836.2011.04607.x
Prohibitins are involved in protease-activated receptor 1-mediated platelet aggregation

Y. Zhang1,†, Y. Wang1,2,†, Y. Xiang1, W. Lee1, Y. Zhang1

Keywords: platelets;prohibitin;thrombin;PAR1 Summary Background: Prohibitins (PHBs), comprising the two homologous members PHB1 and PHB2, are ubiquitously expressed and highly conserved. The membrane PHBs are reported to be involved in typhoid fever, obesity and cancer metastasis. Proteomic studies have revealed the presence of PHBs in human platelets, but the roles of PHBs during platelet aggregation are unknown. Objectives: The present study aimed to investigate the role of PHBs in platelet aggregation. Methods and results: PHB1 and PHB2 were detected on the surface of human platelets using flow cytometry and confocal microscopy. The PHBs were distributed in lipid rafts, as determined by sucrose density centrifugation. In addition, the PHBs were associated with protease-activated receptor 1 (PAR1), as determined by Bm-TFF2 (a PAR1 agonist)-affinity chromatography, co-immunoprecipitation and confocal microscopy. The platelet aggregation, αIIbβ3 activation, granular secretion and calcium mobilization stimulated by low concentrations of thrombin (0.05 U/ml) or PAR1-activating peptide (PAR1-AP, 20 μM) were reduced or abolished as a result of the blockade of PHBs by anti-PHB antibodies or their Fab fragments; however, the same results were not observed when induced by high concentrations of thrombin (0.6 U/ml) or PAR4-AP (300 μM). The calcium mobilization in MEG-01 megakaryocytes stimulated by PAR1-AP was significantly suppressed by PHB depletion using RNA interference against PHB1 and PHB2. Conclusions: PHBs are localized on the human platelet membrane and are involved in PAR1-mediated platelet aggregation. Until recently, PHBs were unknown regulators of PAR1 signaling and may be effective targets for anti-platelet therapy.

参考文献:

Zhang Y, Wang Y, Xiang Y, Lee W, Zhang Y.Prohibitins are involved in protease-activated receptor 1-mediated platelet aggregation.J Thromb Haemost. 2011 Dec 28. doi: 10.1111/j.1538-7836.2011.04607.x.

Kakehashi A, Ishii N, Shibata T, Wei M, Okazaki E, Tachibana T, Fukushima S, Wanibuchi H.Mitochondrial prohibitins and septin 9 are implicated in the onset of rat hepatocarcinogenesis.Toxicol Sci. 2011 Jan;119(1):61-72.

Sievers C, Billig G, Gottschalk K, Rudel T.Prohibitins are required for cancer cell proliferation and adhesion.PLoS One. 2010 Sep 14;5(9):e12735.

Van Aken O, Whelan J, Van Breusegem F.Prohibitins: mitochondrial partners in development and stress response.Trends Plant Sci. 2010 May;15(5):275-82.

Osman C, Merkwirth C, Langer T.Prohibitins and the functional compartmentalization of mitochondrial membranes.J Cell Sci. 2009 Nov 1;122(Pt 21):3823-30.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1791501, encodeId=a1a71e915019c, content=<a href='/topic/show?id=46c414e19c2' target=_blank style='color:#2F92EE;'>#prohibitin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14719, encryptionId=46c414e19c2, topicName=prohibitin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jun 13 16:30:00 CST 2012, time=2012-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008192, encodeId=29f82008192be, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sat Feb 18 20:30:00 CST 2012, time=2012-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795726, encodeId=c6cf1e9572672, content=<a href='/topic/show?id=c9d61e46874' target=_blank style='color:#2F92EE;'>#TINs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17468, encryptionId=c9d61e46874, topicName=TINs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Mon Jun 18 22:30:00 CST 2012, time=2012-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288105, encodeId=8bc91288105e7, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299714, encodeId=66b91299e14c6, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301397, encodeId=cdde130139e41, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497735, encodeId=60d6149e735b1, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601657, encodeId=79f5160165e35, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=)]
    2012-06-13 hmwwww
  2. [GetPortalCommentsPageByObjectIdResponse(id=1791501, encodeId=a1a71e915019c, content=<a href='/topic/show?id=46c414e19c2' target=_blank style='color:#2F92EE;'>#prohibitin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14719, encryptionId=46c414e19c2, topicName=prohibitin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jun 13 16:30:00 CST 2012, time=2012-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008192, encodeId=29f82008192be, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sat Feb 18 20:30:00 CST 2012, time=2012-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795726, encodeId=c6cf1e9572672, content=<a href='/topic/show?id=c9d61e46874' target=_blank style='color:#2F92EE;'>#TINs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17468, encryptionId=c9d61e46874, topicName=TINs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Mon Jun 18 22:30:00 CST 2012, time=2012-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288105, encodeId=8bc91288105e7, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299714, encodeId=66b91299e14c6, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301397, encodeId=cdde130139e41, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497735, encodeId=60d6149e735b1, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601657, encodeId=79f5160165e35, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=)]
    2012-02-18 changfy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1791501, encodeId=a1a71e915019c, content=<a href='/topic/show?id=46c414e19c2' target=_blank style='color:#2F92EE;'>#prohibitin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14719, encryptionId=46c414e19c2, topicName=prohibitin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jun 13 16:30:00 CST 2012, time=2012-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008192, encodeId=29f82008192be, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sat Feb 18 20:30:00 CST 2012, time=2012-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795726, encodeId=c6cf1e9572672, content=<a href='/topic/show?id=c9d61e46874' target=_blank style='color:#2F92EE;'>#TINs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17468, encryptionId=c9d61e46874, topicName=TINs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Mon Jun 18 22:30:00 CST 2012, time=2012-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288105, encodeId=8bc91288105e7, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299714, encodeId=66b91299e14c6, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301397, encodeId=cdde130139e41, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497735, encodeId=60d6149e735b1, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601657, encodeId=79f5160165e35, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=)]
    2012-06-18 xsm918
  4. [GetPortalCommentsPageByObjectIdResponse(id=1791501, encodeId=a1a71e915019c, content=<a href='/topic/show?id=46c414e19c2' target=_blank style='color:#2F92EE;'>#prohibitin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14719, encryptionId=46c414e19c2, topicName=prohibitin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jun 13 16:30:00 CST 2012, time=2012-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008192, encodeId=29f82008192be, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sat Feb 18 20:30:00 CST 2012, time=2012-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795726, encodeId=c6cf1e9572672, content=<a href='/topic/show?id=c9d61e46874' target=_blank style='color:#2F92EE;'>#TINs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17468, encryptionId=c9d61e46874, topicName=TINs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Mon Jun 18 22:30:00 CST 2012, time=2012-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288105, encodeId=8bc91288105e7, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299714, encodeId=66b91299e14c6, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301397, encodeId=cdde130139e41, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497735, encodeId=60d6149e735b1, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601657, encodeId=79f5160165e35, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=)]
    2012-01-21 lsndxfj
  5. [GetPortalCommentsPageByObjectIdResponse(id=1791501, encodeId=a1a71e915019c, content=<a href='/topic/show?id=46c414e19c2' target=_blank style='color:#2F92EE;'>#prohibitin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14719, encryptionId=46c414e19c2, topicName=prohibitin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jun 13 16:30:00 CST 2012, time=2012-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008192, encodeId=29f82008192be, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sat Feb 18 20:30:00 CST 2012, time=2012-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795726, encodeId=c6cf1e9572672, content=<a href='/topic/show?id=c9d61e46874' target=_blank style='color:#2F92EE;'>#TINs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17468, encryptionId=c9d61e46874, topicName=TINs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Mon Jun 18 22:30:00 CST 2012, time=2012-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288105, encodeId=8bc91288105e7, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299714, encodeId=66b91299e14c6, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301397, encodeId=cdde130139e41, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497735, encodeId=60d6149e735b1, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601657, encodeId=79f5160165e35, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=)]
    2012-01-21 lqvr
  6. [GetPortalCommentsPageByObjectIdResponse(id=1791501, encodeId=a1a71e915019c, content=<a href='/topic/show?id=46c414e19c2' target=_blank style='color:#2F92EE;'>#prohibitin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14719, encryptionId=46c414e19c2, topicName=prohibitin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jun 13 16:30:00 CST 2012, time=2012-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008192, encodeId=29f82008192be, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sat Feb 18 20:30:00 CST 2012, time=2012-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795726, encodeId=c6cf1e9572672, content=<a href='/topic/show?id=c9d61e46874' target=_blank style='color:#2F92EE;'>#TINs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17468, encryptionId=c9d61e46874, topicName=TINs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Mon Jun 18 22:30:00 CST 2012, time=2012-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288105, encodeId=8bc91288105e7, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299714, encodeId=66b91299e14c6, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301397, encodeId=cdde130139e41, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497735, encodeId=60d6149e735b1, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601657, encodeId=79f5160165e35, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1791501, encodeId=a1a71e915019c, content=<a href='/topic/show?id=46c414e19c2' target=_blank style='color:#2F92EE;'>#prohibitin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14719, encryptionId=46c414e19c2, topicName=prohibitin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jun 13 16:30:00 CST 2012, time=2012-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008192, encodeId=29f82008192be, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sat Feb 18 20:30:00 CST 2012, time=2012-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795726, encodeId=c6cf1e9572672, content=<a href='/topic/show?id=c9d61e46874' target=_blank style='color:#2F92EE;'>#TINs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17468, encryptionId=c9d61e46874, topicName=TINs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Mon Jun 18 22:30:00 CST 2012, time=2012-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288105, encodeId=8bc91288105e7, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299714, encodeId=66b91299e14c6, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301397, encodeId=cdde130139e41, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497735, encodeId=60d6149e735b1, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601657, encodeId=79f5160165e35, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1791501, encodeId=a1a71e915019c, content=<a href='/topic/show?id=46c414e19c2' target=_blank style='color:#2F92EE;'>#prohibitin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14719, encryptionId=46c414e19c2, topicName=prohibitin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jun 13 16:30:00 CST 2012, time=2012-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008192, encodeId=29f82008192be, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sat Feb 18 20:30:00 CST 2012, time=2012-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795726, encodeId=c6cf1e9572672, content=<a href='/topic/show?id=c9d61e46874' target=_blank style='color:#2F92EE;'>#TINs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17468, encryptionId=c9d61e46874, topicName=TINs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Mon Jun 18 22:30:00 CST 2012, time=2012-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288105, encodeId=8bc91288105e7, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299714, encodeId=66b91299e14c6, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301397, encodeId=cdde130139e41, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497735, encodeId=60d6149e735b1, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601657, encodeId=79f5160165e35, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Jan 21 15:30:00 CST 2012, time=2012-01-21, status=1, ipAttribution=)]
    2012-01-21 sunylz

相关资讯

全球药企心血管疾病新药研发概况

预测任何在研药物的未来市场趋势都需要一些技巧,首先,必须看到试验中的药物相对于目前上市药品的表现,另外,还要清楚批准过程中可能出现的竞争者。最近,美国咨询公司Fiercebiotech从处于晚期开发阶段的的潜力产品中选出了其中的15位佼佼者,我们或许可以将此看作全球新药研发趋势的缩影。   1.Dalcetrapib 治疗领域:心血管疾病 开发者:罗氏 销售预测:50亿~100

Am J Cardiol:维生素D过多摄取或危害心血管健康

人体摄入过多的维生素D是否会危害心血管健康一直是科学界没有解决的问题,虽然长久以来维生素D被认为有提高骨骼健康,保护心脏的功能,但最近,John Hopkins大学的研究人员却发现过高水平的维生素D可能对心血管并没有益处,甚至会对人体造成危害。相关论文刊登在新一期American Journal of Cardiology杂志上。 John Hopkins大学医学院普通内科部的主要研究员——Mu

2011 AHA之右心系统进展

者:同济大学附属上海市肺科医院 荆志成 来源:中国医学论坛报   美国心脏学会(AHA)年会释放出的信息量很大,仅右心领域进展就令人目不暇接。闲暇之时笔者不禁忧虑:当前我国心血管领域原创性理论和技术研究显得不足,操作例数往往是国内学术界“比拼”项目,对科学进步贡献最大因素——革命性的新理论和新技术——常被忽略。客观、设计良好的科学研究才是推动国家科技进步的原动力!   近半数国际肺动脉高

高龄心血管病患者中心血管危险因子的性别差异:PROTEGER研究

    回顾既往的临床研究结果,我们发现男性和女性虽然有着相似的心血管危险因子,但这些危险因子所导致心血管疾病在男女之间却并不相同。例如,男性更容易患有冠心病及心力衰竭,而女性则更易发生高血压和糖尿病。这提示我们,是否这些心血管危险因子在致病机制方面存在着一定的性别差异。此外,女性发生心血管疾病的时间往往要比男性晚10年左右,但在绝经后,女性的心血管疾病的患病率和死亡

空气污染是心血管疾病的危险因子研究

一般认为高血脂、高血压、高血糖、高凝状态是心脑血管病最重要、最直接的危险因子,所谓“Cardiomatabolic Risk Factors”。近年来的研究证明空气污染(Air Pollution),亦是心血管病发病和死亡最重要的危险因子之一。它不仅可以引起血管内皮和血管损伤,促进血栓形成,还可以诱发动脉粥样硬化、心律失常、心肌肥厚、心肌梗塞等多种心血管病,而且还是诱发心脏猝死和急性冠状综合征最重

综述:MicroRNA在心血管疾病诊疗中的研究进展

徐明 北医三院心内科 近年来MicroRNA(miRNA)一直是医学生物学研究的热点。它作为一类非编码的小RNA,参与30-50%基因的转录和表达调控[1, 2],因此人体的众多生命活动和疾病的发病发生、发展都与miRNA的变化密不可分。miRNA的作用因细胞特异性和目标mRNA的不同而异,miRNA可以通过影响细胞的发育、分裂、增殖、凋亡、代谢、再生、可塑性等表型的变化,参与疾病的损伤与修复过